Eidos Therapeutics, Inc

/Eidos Therapeutics, Inc

We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR.

Symbol

Price Range
$15.00 - $17.00

Final Shares
6,250,000

Anticipated Date
TBD

Underwriters

To view the prospectus for IPO, or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC P. O. Box 21154, Mesa, AZ 85277

Secured By miniOrange